Sofosbuvir – Key patent, SPC, and data exclusivity expiry (44 country coverage):Life Sciences Market Research Reports

Life Sciences Market Research Reports

Mobile Game Development Course Learn how to create awesome HTML5 games that run on iPhone, iPad, Android and Desktop! Sign up today for this $99 online course. From our sponsors

Sofosbuvir – Key patent, SPC, and data exclusivity expiry (44 country coverage) Sep 14th 2013, 00:00, by rnrmahesh Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Sofosbuvir Sofosbuvir indications: Treatment of chronic hepatitis C virus optionally in combination with Ledipasvir and/or Ribavirin, or Ribavirin and Peginterferon alpha 2 Sofosbuvir innovator: Gilead Examples of information found in this online report include: # Includes key patent publications for 44 countries (see list below) # Contains SPC protection for every EU state … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=114773. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/sofosbuvir-key-patent-spc-and-data-exclusivity-expiry-44-country-coverage-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions